News - Page 79 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article Opinions | The Facts on Colorado Proposition 122

Opinions | The Facts on Colorado Proposition 122

Post published:November 5, 2022
Post category:Opinions

Read more about the article Psychedelic Bulletin #122: Lusaris Raises $60m to Develop 5-MeO-DMT; First Take-Home Psilocybin Trial in N. America; COMPASS Phase 2b Published in NEJM

Psychedelic Bulletin #122: Lusaris Raises $60m to Develop 5-MeO-DMT; First Take-Home Psilocybin Trial in N. America; COMPASS Phase 2b Published in NEJM

Post published:November 4, 2022
Post category:Psychedelic Bulletin

Read more about the article COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights

COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights

Post published:November 4, 2022
Post category:Press Release

Read more about the article Psychedelic Research Bulletin: October 2022

Psychedelic Research Bulletin: October 2022

Post published:November 3, 2022
Post category:Psychedelics Research Review

Read more about the article Analysis: COMPASS Pathways Phase 2b Psilocybin Trial Published in NEJM

Analysis: COMPASS Pathways Phase 2b Psilocybin Trial Published in NEJM

Post published:November 2, 2022
Post category:Analysis

Read more about the article Lusaris Therapeutics Launches with $60 Million Series A Financing to Redefine the Treatment of Severe Neuropsychiatric and Neurological Disorders

Lusaris Therapeutics Launches with $60 Million Series A Financing to Redefine the Treatment of Severe Neuropsychiatric and Neurological Disorders

Post published:November 2, 2022
Post category:Press Release

Read more about the article atai Life Sciences to Participate in November Investor Events & Healthcare Conferences

atai Life Sciences to Participate in November Investor Events & Healthcare Conferences

Post published:November 2, 2022
Post category:Press Release

Read more about the article PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome

PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome

Post published:November 2, 2022
Post category:Press Release

Read more about the article Braxia Scientific Announces Voting Results from the Annual General and Special Meeting of Shareholders

Braxia Scientific Announces Voting Results from the Annual General and Special Meeting of Shareholders

Post published:November 2, 2022
Post category:Press Release

Read more about the article Numinus Re-Launches “Psychedelic Therapy Frontiers” Podcast with additional hosts and topics

Numinus Re-Launches “Psychedelic Therapy Frontiers” Podcast with additional hosts and topics

Post published:November 1, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.